6855 — Ascentage Pharma International Income Statement
0.000.00%
Last trade - 00:00
- HK$12.22bn
- HK$12.89bn
- CNY221.98m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 14.5 | 12.4 | 27.9 | 210 | 222 |
Cost of Revenue | |||||
Gross Profit | 12.4 | 10.5 | 24.6 | 188 | 191 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,493 | 682 | 843 | 1,044 | 1,060 |
Operating Profit | -1,478 | -669 | -816 | -834 | -838 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1,482 | -675 | -832 | -887 | -933 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,481 | -678 | -782 | -883 | -926 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1,481 | -678 | -782 | -883 | -926 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,481 | -678 | -782 | -883 | -926 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -12.5 | -3.14 | -3.07 | -3.35 | -3.28 |